Cargando…

Induction of NK Cell Reactivity against B-Cell Acute Lymphoblastic Leukemia by an Fc-Optimized FLT3 Antibody

Antibody-dependent cellular cytotoxicity (ADCC) is a major mechanism by which antitumor antibodies mediate therapeutic efficacy. At present, we evaluate an Fc-optimized (amino acid substitutions S239D/I332E) FLT3 antibody termed 4G8-SDIEM (FLYSYN) in patients with acute myeloid leukemia (NCT02789254...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schmied, Bastian J., Lutz, Martina S., Riegg, Fabian, Zekri, Latifa, Heitmann, Jonas S., Bühring, Hans-Jörg, Jung, Gundram, Salih, Helmut R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966676/ https://www.ncbi.nlm.nih.gov/pubmed/31817795 http://dx.doi.org/10.3390/cancers11121966

Ejemplares similares

An Fc-Optimized CD133 Antibody for Induction of NK Cell Reactivity against B Cell Acute Lymphoblastic Leukemia
por: Riegg, Fabian, et al.
Publicado: (2021)

An Fc-Optimized CD133 Antibody for Induction of Natural Killer Cell Reactivity Against Colorectal Cancer
por: Schmied, Bastian J., et al.
Publicado: (2019)

B7-H3-targeting Fc-optimized antibody for induction of NK cell reactivity against sarcoma
por: Hagelstein, Ilona, et al.
Publicado: (2022)

A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALL
por: Mehta, Naveen K, et al.
Publicado: (2022)

Platelets subvert antitumor efficacy of T cell-recruiting bispecific antibodies
por: Lutz, Martina Svenja, et al.
Publicado: (2022)

IgG-based B7-H3xCD3 bispecific antibody for treatment of pancreatic, hepatic and gastric cancer
por: Lutz, Martina S., et al.
Publicado: (2023)

Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease
por: Heitmann, Jonas S., et al.
Publicado: (2023)

Tocilizumab, but not dexamethasone, prevents CRS without affecting antitumor activity of bispecific antibodies
por: Kauer, Joseph, et al.
Publicado: (2020)

Prognostic relevance of HER2/neu in acute lymphoblastic leukemia and induction of NK cell reactivity against primary ALL blasts by trastuzumab
por: Haen, Sebastian P., et al.
Publicado: (2016)

CD18 Antibody Application Blocks Unwanted Off-Target T Cell Activation Caused by Bispecific Antibodies
por: Kauer, Joseph, et al.
Publicado: (2021)

Bispecific Antibodies in Prostate Cancer Therapy: Current Status and Perspectives
por: Heitmann, Jonas S., et al.
Publicado: (2021)

Novel ACE2 fusion protein with adapting activity against SARS-CoV-2 variants in vitro
por: Zekri, Latifa, et al.
Publicado: (2023)

Bispecific NKG2D-CD3 and NKG2D-CD16 fusion proteins for induction of NK and T cell reactivity against acute myeloid leukemia
por: Märklin, Melanie, et al.
Publicado: (2019)

Protocol of a prospective, multicentre phase I study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients with castration-resistant prostate carcinoma
por: Heitmann, Jonas S, et al.
Publicado: (2020)

Identification of CD318 (CDCP1) as novel prognostic marker in AML
por: Heitmann, Jonas S., et al.
Publicado: (2020)

IgG-Based Bispecific Anti-CD95 Antibodies for the Treatment of B Cell-Derived Malignancies and Autoimmune Diseases
por: Hörner, Sebastian, et al.
Publicado: (2022)

NK Cell-Fc Receptors Advance Tumor Immunotherapy
por: Sanseviero, Emilio
Publicado: (2019)

Receptor Activator of NF-κB (RANK) Confers Resistance to Chemotherapy in AML and Associates with Dismal Disease Course
por: Clar, Kim L., et al.
Publicado: (2021)

CD105 (Endoglin) as negative prognostic factor in AML
por: Kauer, Joseph, et al.
Publicado: (2019)

BCR::ABL1 tyrosine kinase inhibitors hamper the therapeutic efficacy of blinatumomab in vitro
por: Kauer, Joseph, et al.
Publicado: (2022)

Expression of the Immune Checkpoint Modulator OX40 in Acute Lymphoblastic Leukemia Is Associated with BCR-ABL Positivity()
por: Rothfelder, Kathrin, et al.
Publicado: (2018)

The challenges of translation
por: Salih, Helmut R, et al.
Publicado: (2019)

How to outsmart NK cell tolerance
por: Terszowski, Grzegorz, et al.
Publicado: (2015)

Bispecific NKG2D-CD3 and NKG2D-CD16 Fusion Proteins as Novel Treatment Option in Advanced Soft Tissue Sarcomas
por: Hagelstein, Ilona, et al.
Publicado: (2021)

Expression and function of FcγRII on NK cells in rhesus macaques
por: He, X, et al.
Publicado: (2012)

An IgG‐based bispecific antibody for improved dual targeting in PSMA‐positive cancer
por: Zekri, Latifa, et al.
Publicado: (2020)

Differential Regulation of NK Cell Receptors in Acute Lymphoblastic Leukemia
por: Lee, Le Jie, et al.
Publicado: (2022)

FcRγ Gene Editing Reprograms Conventional NK Cells to Display Key Features of Adaptive Human NK Cells
por: Liu, Weiru, et al.
Publicado: (2020)

NK Cells as Possible Prognostic Factor in Childhood Acute Lymphoblastic Leukemia
por: Mizia-Malarz, Agnieszka, et al.
Publicado: (2019)

Lack of FLT3-ITD in Tunisian childhood acute lymphoblastic leukemia
por: Frikha, Rim, et al.
Publicado: (2022)

Identification of CD105 (endoglin) as novel risk marker in CLL
por: Greiner, Sarah M., et al.
Publicado: (2022)

Single-cell quantification of functional outcomes of CD16 ligation in NK cells by Fc-engineered antibodies
por: Romain, Gabrielle, et al.
Publicado: (2013)

Engineering Anti-Tumor Monoclonal Antibodies and Fc Receptors to Enhance ADCC by Human NK Cells
por: Dixon, Kate J., et al.
Publicado: (2021)

The wolf in sheep’s clothing: Platelet-derived “pseudo self” impairs cancer cell “missing self” recognition by NK cells
por: Placke, Theresa, et al.
Publicado: (2012)

Cytogenetic Profile and FLT3 Gene Mutations of Childhood Acute Lymphoblastic Leukemia
por: Alkhayat, Nawaf, et al.
Publicado: (2017)

Lymphoblastic T Cells and Mature NK Cells With the Same TCRγ Rearrangement: A Common Origin?
por: Roggy, Anne, et al.
Publicado: (2021)

A “vicious cycle” of NK-cell immune evasion in acute myeloid leukemia mediated by RANKL?
por: Schmiedel, Benjamin Joachim, et al.
Publicado: (2013)

DNAM-1/CD226 is functionally expressed on acute myeloid leukemia (AML) cells and is associated with favorable prognosis
por: Chashchina, Anna, et al.
Publicado: (2021)

Characterization of leukemia-specific NK cell subsets against acute lymphoblastic leukemia in children
por: Babor, Florian, et al.
Publicado: (2014)

FcγRIIIa receptor polymorphism influences NK cell mediated ADCC activity against HIV
por: Talathi, Sneha Pramod, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_cgh4gq6ja1m8to652pe9hahk5j